113 related articles for article (PubMed ID: 17786303)
1. Characteristics of dimeric (bis) bidentate selective high affinity ligands as HLA-DR10 beta antibody mimics targeting non-Hodgkin's lymphoma.
DeNardo GL; Hok S; Van Natarajan A; Cosman M; DeNardo SJ; Lightstone FC; Mirick GR; Yuan A; Perkins J; Sysko VV; Lehmann J; Balhorn RL
Int J Oncol; 2007 Oct; 31(4):729-40. PubMed ID: 17786303
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma.
DeNardo GL; Natarajan A; Hok S; Perkins J; Cosman M; DeNardo SJ; Lightstone FC; Mirick GR; Miers LA; Balhorn RL
J Nucl Med; 2007 Aug; 48(8):1338-47. PubMed ID: 17631545
[TBL] [Abstract][Full Text] [Related]
3. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
West J; Perkins J; Hok S; Balhorn R; Lightstone FC; Cosman M; DeNardo SJ; DeNardo GL
Cancer Biother Radiopharm; 2006 Dec; 21(6):645-54. PubMed ID: 17257080
[TBL] [Abstract][Full Text] [Related]
4. Nanomolecular HLA-DR10 antibody mimics: A potent system for molecular targeted therapy and imaging.
DeNardo GL; Natarajan A; Hok S; Mirick G; DeNardo SJ; Corzett M; Sysko V; Lehmann J; Beckett L; Balhorn R
Cancer Biother Radiopharm; 2008 Dec; 23(6):783-96. PubMed ID: 20443696
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and radiolabeling of selective high-affinity ligands designed to target non-Hodgkin's lymphoma and leukemia.
Hok S; Natarajan A; Balhorn R; DeNardo SJ; DeNardo GL; Perkins J
Bioconjug Chem; 2007; 18(3):912-21. PubMed ID: 17373772
[TBL] [Abstract][Full Text] [Related]
6. Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
Albrecht H; Cosman M; Ngu-Schwemlein M; Corzett M; Curran KW; Dolan C; Fang X; DeNardo SJ; DeNardo GL; Balhorn R
Cancer Biother Radiopharm; 2007 Aug; 22(4):531-42. PubMed ID: 17803448
[TBL] [Abstract][Full Text] [Related]
7. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma/leukemia.
Balhorn R; Hok S; Burke PA; Lightstone FC; Cosman M; Zemla A; Mirick G; Perkins J; Natarajan A; Corzett M; DeNardo SJ; Albrecht H; Gregg JP; DeNardo GL
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5621s-5628s. PubMed ID: 17875798
[TBL] [Abstract][Full Text] [Related]
8. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia.
DeNardo GL; Mirick GR; Hok S; DeNardo SJ; Beckett LA; Adamson GN; Balhorn RL
Int J Oncol; 2009 Feb; 34(2):511-6. PubMed ID: 19148487
[TBL] [Abstract][Full Text] [Related]
9. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors.
Zhang N; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2007 Jun; 22(3):342-56. PubMed ID: 17651040
[TBL] [Abstract][Full Text] [Related]
10. Hexa-arginine enhanced uptake and residualization of selective high affinity ligands by Raji lymphoma cells.
Balhorn R; Hok S; DeNardo S; Natarajan A; Mirick G; Corzett M; Denardo G
Mol Cancer; 2009 Apr; 8():25. PubMed ID: 19383174
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
12. A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas.
Balhorn RL; Skorupski KA; Hok S; Balhorn MC; Guerrero T; Rebhun RB
Vet Immunol Immunopathol; 2010 Oct; 137(3-4):235-42. PubMed ID: 20576295
[TBL] [Abstract][Full Text] [Related]
13. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
14. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
15. The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers.
Balhorn R; Balhorn MC; Balakrishnan K; Rebhun RB
J Drug Target; 2020 Dec; 28(10):1124-1136. PubMed ID: 32588667
[TBL] [Abstract][Full Text] [Related]
16. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
Pagel JM; Pantelias A; Hedin N; Wilbur S; Saganic L; Lin Y; Axworthy D; Hamlin DK; Wilbur DS; Gopal AK; Press OW
Cancer Res; 2007 Jun; 67(12):5921-8. PubMed ID: 17575162
[TBL] [Abstract][Full Text] [Related]
18. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
19. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
